Compare Carlyle Group Inc (CG) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carlyle Group Inc vs GSK plc — how do they compare? Carlyle Group Inc trades at $48.24 (market cap $17.23B), while GSK plc trades at $50.28 (market cap $102.60B). The key difference: GSK plc is far larger — about 6× Carlyle Group Inc's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| CG | GSK | |
|---|---|---|
Market Cap | $17.23B | $102.60B |
Sector | Financials | Health |
52-Week High | $69.35 | $61.18 |
52-Week Low | $40.52 | $38.22 |
Dividend Yield | 2.9% | 3.57% |
Enterprise Value | — | $123.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CG trades at $48.14, up 0.71% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat estimates, with revenue growth and AUM expansion noted. The stock shows positive momentum near key resistance at $50, supported by institutional buying and strategic partnerships.
Outlook is positive given earnings beats and a $59.14 consensus price target, but risks include volatile cash flows and high P/E of 50.36. Investment appeal hinges on sustained fundraising and execution amid economic uncertainty.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
